$1.69 Billion is the total value of Casdin Capital, LLC's 42 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 26.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NVTA | Buy | INVITAE CORP | $273,638,000 | +475.5% | 9,033,943 | +159.7% | 16.19% | +220.8% |
| BPMC | BLUEPRINT MEDICINES CORP | $120,900,000 | +33.4% | 1,550,000 | 0.0% | 7.16% | -25.6% | |
| FATE | Buy | FATE THERAPEUTICS INC | $104,646,000 | +84.8% | 3,050,000 | +19.6% | 6.19% | +3.0% |
| SRPT | Sell | SAREPTA THERAPEUTICS INC | $84,980,000 | +29.7% | 530,000 | -20.9% | 5.03% | -27.7% |
| MYOK | Sell | MYOKARDIA INC | $84,059,000 | +80.2% | 870,000 | -12.6% | 4.98% | +0.5% |
| ALNY | Sell | ALNYLAM PHARMACEUTICALS INC | $81,461,000 | +27.9% | 550,000 | -6.0% | 4.82% | -28.7% |
| BLFS | Buy | BIOLIFE SOLUTIONS INC | $79,290,000 | +238.1% | 4,849,524 | +96.5% | 4.69% | +88.5% |
| BLUE | BLUEBIRD BIO INC | $67,449,000 | +32.8% | 1,105,000 | 0.0% | 3.99% | -26.0% | |
| AGIO | AGIOS PHARMACEUTICALS INC | $57,224,000 | +50.7% | 1,070,000 | 0.0% | 3.39% | -16.0% | |
| CDXS | Sell | CODEXIS INC | $53,497,000 | -5.5% | 4,692,732 | -7.5% | 3.17% | -47.3% |
| BNR | New | BURNING ROCK BIOTECH LTDsponsored ads | $46,749,000 | – | 1,730,786 | +100.0% | 2.77% | – |
| TWST | TWIST BIOSCIENCE CORP | $45,300,000 | +48.1% | 1,000,000 | 0.0% | 2.68% | -17.4% | |
| CDNA | Sell | CAREDX INC | $42,280,000 | +49.6% | 1,193,335 | -7.8% | 2.50% | -16.6% |
| RVMD | Buy | REVOLUTION MEDICINES INC | $42,131,000 | +45.7% | 1,334,536 | +1.1% | 2.49% | -18.8% |
| ADVM | Buy | ADVERUM BIOTECHNOLOGIES INC | $38,941,000 | +254.3% | 1,865,000 | +65.8% | 2.30% | +97.5% |
| ADPT | Sell | ADAPTIVE BIOTECHNOLOGIES COR | $34,501,000 | +56.6% | 713,125 | -10.1% | 2.04% | -12.7% |
| GBIO | New | GENERATION BIO CO | $33,835,000 | – | 1,611,214 | +100.0% | 2.00% | – |
| DNLI | Sell | DENALI THERAPEUTICS INC | $31,676,000 | +24.3% | 1,310,000 | -10.0% | 1.88% | -30.7% |
| CNST | CONSTELLATION PHARMCETICLS I | $29,449,000 | -4.4% | 980,000 | 0.0% | 1.74% | -46.7% | |
| BGNE | New | BEIGENE LTDsponsored adr | $28,260,000 | – | 150,000 | +100.0% | 1.67% | – |
| ALLO | Buy | ALLOGENE THERAPEUTICS INC | $26,763,000 | +175.3% | 625,000 | +25.0% | 1.58% | +53.5% |
| FULC | Buy | FULCRUM THERAPEUTICS INC | $26,359,000 | +82.6% | 1,441,176 | +19.2% | 1.56% | +1.8% |
| ALEC | ALECTOR INC | $26,298,000 | +1.3% | 1,076,039 | 0.0% | 1.56% | -43.5% | |
| MGTA | Buy | MAGENTA THERAPEUTICS INC | $25,129,000 | +34.7% | 3,346,034 | +12.6% | 1.49% | -24.9% |
| AMRS | New | AMYRIS INC | $22,842,000 | – | 5,349,376 | +100.0% | 1.35% | – |
| CRSP | CRISPR THERAPEUTICS AGnamen akt | $19,580,000 | +73.3% | 266,430 | 0.0% | 1.16% | -3.3% | |
| GBT | GLOBAL BLOOD THERAPEUTICS IN | $18,939,000 | +23.6% | 300,000 | 0.0% | 1.12% | -31.1% | |
| Buy | DERMTECH INC | $18,900,000 | +235.0% | 1,428,572 | +149.9% | 1.12% | +86.8% | |
| ZLAB | ZAI LAB LTDadr | $15,605,000 | +59.5% | 190,000 | 0.0% | 0.92% | -11.0% | |
| SGMO | SANGAMO THERAPEUTICS INC | $13,037,000 | +40.7% | 1,455,000 | 0.0% | 0.77% | -21.5% | |
| GRTS | Sell | GRITSTONE ONCOLOGY INC | $12,286,000 | -7.0% | 1,850,373 | -18.5% | 0.73% | -48.1% |
| BDTX | BLACK DIAMOND THERAPEUTICS I | $12,201,000 | +69.0% | 289,395 | 0.0% | 0.72% | -5.7% | |
| ILMN | ILLUMINA INC | $11,111,000 | +35.6% | 30,000 | 0.0% | 0.66% | -24.4% | |
| BMYRT | Buy | BRISTOL-MYERS SQUIBB COright | $10,561,000 | +11.2% | 2,950,000 | +18.0% | 0.62% | -38.0% |
| ORTX | Buy | ORCHARD THERAPEUTICS PLCads | $9,900,000 | +34.8% | 1,650,000 | +69.2% | 0.59% | -24.8% |
| VYGR | Sell | VOYAGER THERAPEUTICS INC | $9,465,000 | -5.5% | 750,000 | -31.5% | 0.56% | -47.4% |
| ORIC | New | ORIC PHARMACEUTICALS INC | $8,484,000 | – | 251,515 | +100.0% | 0.50% | – |
| LEGN | New | LEGEND BIOTECH CORPsponsored ads | $5,746,000 | – | 135,000 | +100.0% | 0.34% | – |
| TPTX | TURNING POINT THERAPEUTICS I | $4,844,000 | +44.6% | 75,000 | 0.0% | 0.29% | -19.4% | |
| ZYME | New | ZYMEWORKS INC | $4,689,000 | – | 130,000 | +100.0% | 0.28% | – |
| DCPH | Sell | DECIPHERA PHARMACEUTICALS IN | $3,882,000 | -32.7% | 65,000 | -53.6% | 0.23% | -62.4% |
| STOK | STOKE THERAPEUTICS INC | $2,860,000 | +4.1% | 120,000 | 0.0% | 0.17% | -42.1% | |
| SAGE | Exit | SAGE THERAPEUTICS INC | $0 | – | -385,000 | -100.0% | -1.17% | – |
| GILD | Exit | GILEAD SCIENCES INC | $0 | – | -175,000 | -100.0% | -1.39% | – |
| GNMK | Exit | GENMARK DIAGNOSTICS INC | $0 | – | -3,365,000 | -100.0% | -1.47% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
| BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
| CODEXIS INC | 22 | Q3 2023 | 8.1% |
| SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
| BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
| ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
| Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
| Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
| Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-18 |
| SC 13D/A | 2024-04-08 |
| 4 | 2024-03-28 |
| 3 | 2024-03-25 |
| 4 | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 4 | 2024-03-06 |
| 4 | 2024-03-06 |
| 13F-HR | 2024-02-14 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.